effect of Royal jelly on sexual function in patients undergoing percutaneous coronary intervention

Investigation of the effect of Royal jelly on sexual function in patients undergoing percutaneous coronary intervention: A randomized, double-blind, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180205038626N13

Enrollment

Registered

2023-11-06

Start date

2023-11-22

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischaemic heart diseases. Ischaemic heart diseases

Interventions

Intervention 1: Intervention group: cardiac patients undergoing angioplasty in the 3rd phase of cardiac rehabilitation, one capsule containing 1000 mg of royal jelly will be prescribed daily for 8 wee

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Cardiac patients undergoing angioplasty in phase 3 of cardiac rehabilitation Married Patients with an age range of 20 to 70 years The score of sexual function questionnaire in men is less than 26 and in women less than 23

Exclusion criteria

Exclusion criteria: Symptomatic cardiac patients Candidate for stenting in another vessel History of urological diseases History of Viagra drug use Taking antidepressants Change in the patient's disease treatment plan during the study? Changing the type of drugs used, effective factors studied Reluctance to continue the study or cause any dissatisfaction regarding the consuming royal jelly or participation in the study Body mass index greater than 35 Taking warfarin

Design outcomes

Primary

Measure	Time frame
Sexual function. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: FSFI questionnaire, IIEF questionnaire.	—

Secondary

Measure	Time frame
Depression. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: 13-question short form depression questionnaire.;Serum lipid profile levels (triglycerides, total cholesterol, LDL-C and HDL-C). Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: BT2000 device.;Prothrombin Time. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA device.;Partial Thromboplastin Time. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA device.;Mean systolic and diastolic blood pressure. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Pressure indicator.;Erythrocyte sedimentation rate. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA device.;C-reactive protein. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA device.	—

Measure

Time frame

Depression. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: 13-question short form depression questionnaire.;Serum lipid profile levels (triglycerides, total cholesterol, LDL-C and HDL-C). Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: BT2000 device.;Prothrombin Time. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA device.;Partial Thromboplastin Time. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA device.;Mean systolic and diastolic blood pressure. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Pressure indicator.;Erythrocyte sedimentation rate. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA device.;C-reactive protein. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: ELISA device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Ahmadnia

Rasht University of Medical Sciences

zahmadnia1365@gmail.com+98 13 3366 9064

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026